References
- Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001; 22:269-76; PMID:11323286; http://dx.doi.org/10.1016/S1471-4906(01)01896-8
- Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009; 21:200-8; PMID:19285848; http://dx.doi.org/10.1016/j.coi.2009.02.004
- Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol 2014; 35:61-8; PMID:24215739; http://dx.doi.org/10.1016/j.it.2013.10.004
- Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012; 18:1248-53; PMID:22772464; http://dx.doi.org/10.1038/nm.2856
- Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012; 24:217-24; PMID:22245556; http://dx.doi.org/10.1016/j.coi.2011.12.011
- Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, Bae EA, Lee GE, Jeon H, Cho J et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med 2015; 21:1010-7; PMID:26280119; http://dx.doi.org/10.1038/nm.3922
- Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007; 70:1-11; PMID:17559575; http://dx.doi.org/10.1111/j.1399-0039.2007.00869.x
- Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012; 122:4160-71; PMID:23064366; http://dx.doi.org/10.1172/JCI65459
- Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, Minze L, Fu YX, Ghobrial RM, Liu W et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun 2015; 6:8266; PMID:26365427; http://dx.doi.org/10.1038/ncomms9266
- Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling G. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015; 16:609-17; PMID:25915731; http://dx.doi.org/10.1038/ni.3159